Screener
Allogene Therapeutics ALLO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
FAQ
- What is Allogene Therapeutics's EPS (diluted)?
- Allogene Therapeutics (ALLO) reported EPS (diluted) of -$0.18 in Q1 2026.
- How has Allogene Therapeutics's EPS (diluted) changed year-over-year?
- Allogene Therapeutics's EPS (diluted) increased by 35.7% year-over-year, from -$0.28 to -$0.18.
- What is the long-term trend for Allogene Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Allogene Therapeutics's EPS (diluted) has grown at a -10.4% compound annual growth rate (CAGR), from -$1.35 to -$0.87.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Allogene Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude